Oncolytics Biotech Inc T.ONC

ASCO

[venture009]

From the information to be released what news would be considered exceptional news and would propel the share price to atmospheric heights? Would it be confirmation that pela turns cold tumors hot or something else? Anything not clear and concise will once again result in uncertainty and a lack of interest will return.

[westcoast1000]

In reply to venture 009' The IND study of a few years back with the surprisingly good results showed the following: mOS 21.0 months vs 10.8 months mOS is median overall survival. If we do that well again, it is a big success. Howevrer all patients need

[inthno]

I have been trying to find more information on this but I do know that not all patients in a trial need to expire to calculate overall survival. I am not sure of the formula but do know that there is supposedly a cutoff that calculates it and once that point is reached that os can be calculated. I do believe that onc is also calculatiing evolving os for the bracelet trial if I heard that correctly

[venture009]

Thanks Westcoast. Although an increase in survival would certainly validate pela's advocacy I am not certain it would provide the desired effect on the sp. Already they have shown impressive survival numbers and it has done very little to propel the share price. Geneman, who I followed on the V2 board years ago, suggested more information on turning cold tumors hot might do it. Of course

[Geneman2004]

I think OS triggers at 80% of events (deaths) or something like that